Invion Updates Director Interest Disclosure to Strengthen Governance

An update from Invion ( (AU:IVX) ) is now available.

Invion has clarified that earlier director interest notices for executive chair and CEO Thian Chew did not include certain interests held by substantial shareholder Honsue Cho and his associates, as these were not strictly required under ASX Listing Rules. The board has now opted, in the interests of stronger corporate governance and alignment with a recent substantial holder notice, to lodge an updated Appendix 3Y for Chew and has reaffirmed that the company remains compliant with ASX disclosure requirements on directors’ interests.

The move underscores Invion’s emphasis on transparency around shareholdings linked to its leadership and major investors, which may reassure regulators and shareholders about the robustness of its governance arrangements. By proactively expanding disclosures beyond minimum regulatory obligations, the company is seeking to strengthen market confidence while it continues to advance its Photosoft-based photodynamic therapy portfolio in oncology and infectious disease markets.

More about Invion

Invion is an ASX-listed life sciences company focused on developing Photosoft photodynamic therapy technology for treating cancers, atherosclerosis and infectious diseases. The company holds extensive exclusive licensing and distribution rights for Photosoft across Australia, New Zealand, much of Asia-Pacific, parts of Asia and Oceania, and North America, with research and clinical cancer trials funded by licensor RMW Cho Group.

YTD Price Performance: -35.48%

Average Trading Volume: 79,546

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$5.82M

For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.